Chirorab, previously known as Rabipur, is an inactivated rabies virus of the strain Flury LEP.
Chiron Behring Vaccines is re-launching Rabipur which is a purified chick embryo cell (PCEC) vaccine. It will continue to be manufactured at its WHO pre-qualified facility in Ankleshwar, Gujarat.
Chirorab is a vaccine which is used for active pre and post-exposure immunization against Rabies.
The immunogenicity, efficacy, and safety of Chirorab have been assessed in several clinical trials in pre- and post-exposure regimens, using both intramuscular and intradermal routes of administration.
Chirorab may be used to boost individuals previously immunized with any human diploid cell rabies vaccine.
Post exposure prophylaxis should commence as soon as possible after exposure.
Anaphylactic reactions including anaphylactic shock that are very rare but clinically severe, and potentially lethal, systemic allergic reactions, can occur following vaccination.
Mild allergic reactions, including rashes (very common) and urticaria (common), may occur after vaccination. These reactions are usually mild in nature and typically resolve within a few days.
Very rare cases with symptoms of Encephalitis and Guillain-Barré Syndrome have been reported.
In clinical trials, the most commonly reported solicited adverse reactions were injection site pain (30-85%) or injection site induration (15-35%). Most injection site reactions were not severe and resolved within 24 to 48 hours.
November 13, 2019: Chiron Behring Vaccines, part of Bharat Biotech International Ltd. announced the relaunch of Rabipur as Chirorab.
“In our ongoing commitment to address the supply shortages of rabies vaccine, we are making additional investments to increase production capacities to over 15 million doses annually,” said Dr. Krishna Ella, CMD, Bharat Biotech.
Clinical Trial NCT02545517: A Clinical Study to Evaluate Immune Responses to Rabies Vaccine in Adults Who Received Different Primary Rabies Vaccination Regimens
- GlaxoSmithKline (GSK) Biologicals' Rabipur vaccine is indicated for active immunization against rabies in individuals of all ages.
- This includes pre-exposure prophylaxis (PrEP), in both primary series and booster dose, and post-exposure prophylaxis.
- The aim of this extension study is to evaluate the long-term (up to approx.10 years) persistence and to assess the boostability of immune responses in subjects who received a primary series of accelerated or conventional rabies PrEP IM regimen No new subjects were enrolled in this study.